Table 1 Stakeholders contributing to each phase
From: Target Product Profiles for medical tests: a systematic review of current methods
Stakeholder groups contributing to each phasea | Scoping | Drafting | Consensus-building |
|---|---|---|---|
n (%) | n (%) | n (%) | |
Researchers | 14 (32) | 15 (34) | 14 (32) |
Industry representatives | 11 (25) | 11 (25) | 14 (32) |
International public organisations | 9 (20) | 12 (27) | 12 (27) |
Clinicians | 7 (16) | 8 (18) | 8 (18) |
Representatives of countries and national disease programs | 5 (11) | 4 (9) | 8 (18) |
Policy makers | 4 (9) | 5 (11) | 4 (9) |
Laboratory experts | 3 (7) | 5 (11) | 3 (7) |
Technical/funding agencies | 2 (5) | 3 (7) | 4 (9) |
Microbiologists | 2 (5) | 4 (9) | 2 (5) |
Implementers | 2 (5) | 2 (5) | 5 (11) |
Patient advocates | 2 (5) | 1 (2) | 3 (7) |
Non-profit sector | 1 (2) | 2 (5) | 4 (9) |
Modellers | 1 (2) | 1 (2) | 1 (2) |
Health economists | 0 (0) | 2 (5) | 2 (5) |
Donors | 2 (5) | 3 (7) | 1 (2) |
Market experts | 2(5) | 1 (2) | 1 (2) |
Program manager | 1 (2) | 2 (5) | 2 (5) |
Scientific associations | 1 (2) | 3 (7) | 2 (5) |
Strategists | 1 (2) | 1 (2) | 0 (0) |
Expert (unspecific) | 1 (2) | 3 (7) | 3 (7) |
Others | 2 (5) | 2 (5) | 1 (2) |